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Abstract
Introduction: The micro-inserts used in the hysteroscopic sterilization procedure elicit a benign occlusive tissue
response leading to permanent tubal occlusion. Little is known about whether immunosuppressed patients mount the
immunological response necessary to ensure tubal occlusion. Theoretical concern for non-occlusion has limited the
use of hysteroscopic sterilization in patients on immunosuppressive therapies.
In all patient populations, if an intrauterine device is in place, it is usually removed at the time of hysteroscopic
sterilization. Little is known about maintaining intrauterine devices during the 3-month period to tubal occlusion.
Case presentation: Our patient in case 1 was a 35-year-old Hispanic woman, gravida 2, para 2002, with a history
of a living donor kidney transplant. Our patient in case 2 was a 32-year-old Hispanic woman, gravida 3, para 2103,
diagnosed with undifferentiated autoimmune disease. Both patients underwent hysteroscopic sterilization. In both
cases, a levonorgestrel intrauterine device was in place for contraception. At the time of micro-insert placement, our
patients were both on daily immunosuppressive medications, including long-term glucocorticoids. Three months after
the hysteroscopic procedure, both patients had successful tubal occlusion, demonstrated by a hysterosalpingogram.
Conclusion: Hysteroscopic sterilization in an outpatient setting is a reasonable option for sterilization in
immunocompromised patients on immunosuppressive therapies. Intrauterine devices can be maintained
during the procedure and during the 3-month period to tubal occlusion.
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Introduction
The Essure® permanent birth control system (Bayer
HealthCare Pharmaceuticals Inc., Whippany, NJ, USA.)
was first approved by the US Food and Drug Adminis-
tration in 2002 and has since been used in approxi-
mately 450,000 sterilization procedures worldwide [1].
The Essure® system is an outpatient hysteroscopic
sterilization procedure that provides permanent contra-
ception through transcervical hysteroscopic placement
of micro-inserts into the proximal portion of each fallo-
pian tube. The system has a 99.74 % effectiveness rate
with a 0.26 % failure rate due to device expulsion, uter-
ine perforation at the time of device placement, im-
proper placement of the device, lack of appropriate
follow-up, and luteal phase pregnancies prior to device
placement [1]. Each Essure® micro-insert is 40 mm in
length and 0.8 mm in diameter and consists of a stain-
less steel inner coil, a nickel titanium elastic outer coil,
and polyethylene terephthalate fibers. When released
from the delivery system, the outer coil expands to 1.5–
2.0 mm to anchor the insert into the fallopian tube [2].
Over time, the polyethylene terephthalate fibers within
the micro-insert trigger a benign chronic inflammatory
and fibrotic response which results in permanent tubal
occlusion [3]. Additional birth control is needed until
tubal occlusion is confirmed at 3 months by a hystero-
salpingogram (HSG) [1].
Histologically, the polyethylene terephthalate fibers
produce an immediate local inflammatory response
with macrophages, fibroblasts, foreign body giant cells,
and plasma cells [3]. A foreign body inflammatory reac-
tion is also elicited by the polyethylene terephthalate
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fiber, which peaks after the device has been in place for
2–3 weeks. After the device is in place for 8–30 weeks,
chronic inflammation and fibrosis predominates the
tissue response. Ultimately, strong fibrotic and inflam-
matory responses between the inner and outer coil of
the micro-insert lead to ingrowth of loose and dense
fibrous tissues, producing tubal occlusion and perman-
ent sterilization [3].
Currently, the instructions for use included in each
Essure® kit contain the following warning: “Patients
undergoing immunosuppressive therapy are discour-
aged from undergoing the Essure® procedure because
the immunosuppressant may lead to decreased tissue
in-growth” [4]. These theoretical concerns regarding
efficacy of hysteroscopic sterilization cause this method of
sterilization to be underutilized in a patient population
that could greatly benefit from a minimally invasive op-
tion. Current literature includes only one case report that
documents a successful hysteroscopic sterilization in a
38-year-old kidney transplant recipient who was on my-
cophenolate (CellCept) 250 mg twice a day and siroli-
mus 2 mg daily [5]. To the best of our knowledge, there
is no literature on immunocompromised patients who
had hysteroscopic sterilization and maintained their
previously placed levonorgestrel (LNG) intrauterine de-
vice (IUD) during the time to tubal occlusion.
In a retrospective case review of 174 patients receiv-
ing Essure® sterilization at the University of Colorado
Hospital between February 2008 and August 2013, two
patients were on immunosuppressive therapies at the
time of the procedure. In this report, we present these
two patients who had HSG-confirmed successful hys-




Our patient was a 35-year-old Hispanic woman, gravida
2, para 2002, with a history of a living donor kidney
transplant at age 23 secondary to hypertensive nephro-
sclerosis. Her maintenance immunosuppressive therapy
included mycophenolate mofetil (CellCept) 1000 mg
twice a day, prednisone 5 mg daily, and tacrolimus 3
mg twice a day. After her second pregnancy was com-
plicated by A2 gestational diabetes, she wanted per-
manent sterilization. However, her gynecologist felt
that her immunosuppression was a contraindication to
micro-insert placement and she had a LNG IUD placed
instead. After 5 years of LNG IUD use, she continued
to want hysteroscopic sterilization. She had normal kid-
ney function and was stable on her medication regimen.
After consultation and a thorough review of the risks of
the procedure at our University-based Family Planning
Clinic, our patient was scheduled for hysteroscopic
sterilization in the outpatient setting with oral sedation
(hydrocodone 10 mg and lorazepam 1 mg). Ketorolac
was not administered owing to her history of renal
transplant.
The Essure® procedure was uncomplicated; two coils
were visualized in her uterine cavity following left-sided
placement and four coils were visualized on her right
side. The procedure was done with the LNG IUD in
place. Prophylactic antibiotics were not administered.
Three months later, HSG showed bilateral occlusion of
her fallopian tubes and the LNG IUD was subsequently
removed.
Case 2
Our patient was a 32-year-old Hispanic woman, gravida
3, para 2103, with a history of undifferentiated auto-
immune disease and polymyositis, diagnosed 17 months
prior to the hysteroscopic sterilization procedure. She
was on mycophenolate mofetil (CellCept) 1500 mg
twice a day and methylprednisolone 2 mg twice a day.
Our patient was originally started on methylpredniso-
lone 16 mg twice a day 1 year prior to her hystero-
scopic sterilization procedure, which was subsequently
tapered to 2 mg daily by 1 month after the sterilization
procedure. Her autoimmune disease and polymyositis
symptoms were well controlled with this medication
regimen. Results from laboratory tests were also mark-
edly improved, including estimated sedimentation rate
and creatine kinase level, at the time of procedure. Our
patient had a LNG IUD in place for 5 years with no
adverse effects, but wanted permanent sterility. After
consultation at our University-based Family Planning
Clinic, our patient was scheduled for hysteroscopic
sterilization in the outpatient setting with oral sedation
(hydrocodone 10 mg and lorazepam 1 mg) and 60 mg
of intramuscular ketorolac.
Micro-insert placement was uncomplicated; three
coils were visualized in her uterine cavity following
both left-side and right-side placement. The procedure
was done while leaving the LNG IUD in place. Prophy-
lactic antibiotics were not administered. Three months
later, HSG showed bilateral occlusion of her fallopian
tubes and the LNG IUD was subsequently removed.
Conclusions
These cases demonstrate successful tubal occlusion
with the hysteroscopic sterilization system in two pa-
tients taking immunosuppressive medications (B and T
lymphocyte inhibitors and chronic steroids). Each pa-
tient used a LNG IUD prior to the procedure, and the
IUDs were left in place during the time to tubal occlu-
sion. There were no adverse events related to maintain-
ing the IUDs. Bilateral tubal occlusion was confirmed
in both patients at 3 months with HSG.
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Bilateral tubal occlusion with the Essure® system
relies on the patient’s ability to mount a foreign body
reaction to the polyethylene terephthalate fibers in
the coil [3]. Owing to theoretical concerns that im-
munosuppressants will interfere with this reaction,
hysteroscopic sterilization in immunosuppressed women
is discouraged by the manufacturer. However, the foreign
body reaction consists primarily of macrophages, fibro-
blasts, and foreign body giant cells [3]. Immunosuppres-
sive medications are thought to have minimal effect on
macrophage activity and the other cell types involved are
not typical targets of most immunosuppressive therapies.
Most immunosuppressive therapies prevent the prolifera-
tion and activation of B and T lymphocytes of the adaptive
immune system [6]. Therefore, these medications should
not interfere with the foreign body response to the micro-
inserts or the chronic inflammation and fibrosis that leads
to tubal occlusion. In the two cases presented here, both
patients were on medications that are thought to inhibit
the proliferation of B and T lymphocytes. In the afore-
mentioned case report from 2012, successful tubal occlu-
sion was demonstrated in a patient on mycophenolate
mofetil (CellCept) 250 mg twice a day and sirolimus 2 mg
daily, both B and T cell suppressants [5]. Unlike our pa-
tients, this patient was not taking glucocorticoids.
Systemic glucocorticoids affect the immune system by
inhibiting the transcription of various pro-inflammatory
cytokines and promoting the transcription of anti-
inflammatory cytokines. Because foreign body cells are
responsive to cellular signals and participate in the
inflammatory response through production of cytokines,
glucocorticoids could theoretically alter the foreign body
reaction to the micro-inserts [7]. However, both patients
presented in this report were on chronic glucocorticoids
and they mounted the appropriate immune response to
the micro-inserts. It is likely that with the multitude of
different cytokines produced during a foreign body
reaction, sufficient pro-inflammatory cytokines are still
present and occlusion of the tubes is successful. In
addition to the foreign body response, the micro-inserts
also produce chronic inflammation and tissue in-growth
with fibrosis, both of which contribute to permanent
sterilization [3].
Organ transplant recipients and patients with auto-
immune disorders are at increased risk of pregnancy-
related complications, including Cesarean section,
gestational diabetes, preeclampsia, preterm delivery,
small for gestational age, intrauterine growth restric-
tion, and intrauterine fetal death [6, 8, 9]. Hystero-
scopic sterilization in the outpatient setting allows
these patients with medical complications to obtain
sterilization while avoiding additional surgery and
general anesthesia. Hysteroscopic sterilization should
be offered as an option for these patients. Medications
that inhibit B and T cell proliferation should not affect
efficacy. Steroid use can be presented as a theoretical
risk for non-occlusion. However, in these two patients
on glucocorticoids, adequate tissue in-growth occurred
and bilateral tubal occlusion was seen. More research is
needed to further elicit the effects of specific steroids
and their dosages on the tissue response to micro-
insert placement.
Continuing to use another form of contraception
until bilateral tubal occlusion is documented by HSG
is paramount in all patients who undergo hystero-
scopic sterilization. These two cases not only demon-
strate that hysteroscopic sterilization can be successful in
patients on immunosuppressant therapies, but that IUDs
can be maintained during and after the hysteroscopic
sterilization procedure. As with many patients with
medical complications, avoiding additional surgery and
general anesthesia makes the hysteroscopic approach to
sterilization attractive. The use of this sterilization tech-
nique, and maintenance of IUDs until tubal occlusion is
documented, should be considered a viable option for
patients on immunosuppressive therapies.
Consent
Written informed consent was obtained from the pa-
tients for publication of this case report. A copy of the
written consent is available for review by the Editor-in-
Chief of this journal.
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